Skip to main content

#Comparison of #patients presenting to #emergency departments infected with #RSV versus #influenza virus: a retrospective cohort study

Abstract

Objective

In recent years, there has been increased awareness of the impact of respiratory syncytial virus (RSV) on adult health, especially in elderly patients. Unlike influenza infection, its presentation and patient outcomes are not well studied. The aim of this study was to compare clinical outcomes in emergency department patients infected by RSV vs influenza.

Methods

This was a multicenter retrospective study in seven emergency departments (ED) in France. Patients with a laboratory-confirmed RSV or influenza infection in the ED were included between January 2017 and December 2022. The primary endpoint was in-hospital mortality truncated at day 28. Secondary endpoints included one year occurrence of thrombo-embolic event, acute coronary syndrome, and stroke.

Results

3397 patient charts were screened, and 3224 were analyzed. Of these, 551 (17%) patients had RSV-positive PCR, and 2673 (83%) had influenza-positive PCR. Patients with RSV were older (median age 73 vs.68; difference, -5.00 percentage points [CI, -4.0 to -6.0 percentage points])), and had more comorbidities (15.0% vs 22.0% difference, -6.92 percentage points [CI, -10.6 to -3.21 percentage points])), compared to those with influenza. There was no significant difference in in-hospital mortality rate at day 28: 3.82% for influenza vs. 4.72% for RSV (adjusted OR 0.93, 95%CI [0.59 to 1.46] p=0.73). There was no significant difference in the occurrence of the secondary endpoints.

Conclusions

In this large study of ED patients, although RSV patients were more fragile, no significant differences were found in in-hospital mortality or the occurrence of cardiovascular or thromboembolic events between RSV and influenza infections.

Source: Journal of Clinical Virology, https://www.sciencedirect.com/science/article/abs/pii/S1386653225000162?dgcid=rss_sd_all

____

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...